← Back to Search

Monoclonal Antibodies

OS2966 for Malignant Glioma

Phase 1

Waitlist Available

Research Sponsored by OncoSynergy, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

Study Summary

This trial will test if the investigational drug OS2966 is safe and well tolerated when delivered directly to the brain of adult participants with recurrent/progressive high-grade glioma.

Eligible Conditions

Malignant Glioma
Brain Tumor
Glioblastoma
Anaplastic Astrocytoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of qualifying treatment emergent adverse events or dose limiting toxicities

Optimal Biological Dose

Secondary outcome measures

Spatial Distribution of OS2966 when delivered via CED

Time to Progression

Tumor Response Rate

Trial Design

1Treatment groups

Experimental Treatment

Group I: Direct Infusion of OS2966Experimental Treatment2 Interventions

OS2966 will be directly infused into the brain tumor and surrounding tumor infiltrated brain via convection-enhanced delivery

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Gadoteridol

2015

Completed Early Phase 1

~40

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

OncoSynergy, Inc.Lead Sponsor

Infuseon Therapeutics, Inc.Industry Sponsor

3 Previous Clinical Trials

12 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What evidence suggests OS2966 is a secure treatment option?

"As this is a Phase 1 trial, with limited information regarding efficacy and safety, OS2966 received a score of 1."

Answered by AI

Is this medical study an unprecedented endeavor?

"Presently, OncoSynergy Inc. is running two trials for OS2966 across 20 cities and 4 nations. The first trial began in 2021 with 24 participants; since then, a further five studies have been conducted."

Answered by AI

In what type of medical scenarios is OS2966 typically prescribed?

"The most frequent therapy for head conditions is OS2966. This pharmaceutical also has proven beneficial in managing magnetic resonance imaging (MRI) scans, magnetic resonance angiography, and vertebral column issues."

Answered by AI

Is there currently an effort to enlist individuals in this clinical experiment?

"The trial's presence on clinicaltrials.gov indicates that it is presently accepting patients. This research project was initially made available to the public on March 2nd 2021 and its information has been revised as of July 11th 2022."

Answered by AI

How many participants are actively participating in this experiment?

"Affirmative, according to the information on clinicaltrials.gov, this medical experiment is actively recruiting patients who have been diagnosed with certain conditions. The trial was initially listed on March 2nd 2021 and has recently undergone updates as of July 11th 2022. 24 individuals are needed from a single medical centre for participation in this study."

Answered by AI

Has OS2966 been explored in other scientific investigations?

"Presently, two clinical trials for OS2966 are being conducted. Neither of these is in Phase 3; however, 33 different medical sites across Seongnam-si, Gyeonggi-do are participating in the research."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection

2021. "Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04608812.